Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06172127Phase 2Active Not Recruiting
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
PrincipalinvestigatorStart date: 2024-07-22
NCT07619066Phase 2Not Yet Recruiting
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
Advanced Breast CancerHER2 MutationHormone Receptor Positive / HER2-negative Breast Cancer
Principalinvestigator

Research Network

Collaboration Network

4 collaborators·4 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Antonio Llombart-Cussac, MD

Arnau de Vilanova Hospital, Valencia (Spain)

Moderately Similar
3 trials

Shared therapeutic areas:

Advanced Breast CancerHER2-positive Breast CancerHER2-positive unresectable locally recurrent or metastatic breast cancer (MBC).

Worked with same sponsors:

Hoffmann-La RocheMedSIR
Collaborated on 1 trial
Similarity Score34%

José M Pérez-García, MD

International Breast Cancer Center (Spain)

Related
1 trials

Shared therapeutic areas:

HER2-positive Breast CancerHER2-positive unresectable locally recurrent or metastatic breast cancer (MBC).

Worked with same sponsors:

Hoffmann-La RocheMedSIR
Collaborated on 1 trial
Similarity Score24%

Tracy E Crane, Phd, RDN

University of Miami

Related
5 trials

Shared therapeutic areas:

Advanced Breast CancerHER2-positive Breast Cancer
Similarity Score10%

Jonathan McConathy, MD, PhD

University of Alabama at Birmingham

Related
6 trials

Shared therapeutic areas:

HER2-positive Breast Cancer
Similarity Score5%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
11 trials

Shared therapeutic areas:

Advanced Breast Cancer
Similarity Score5%

Shanu Modi, MD

Memorial Sloan Kettering Cancer Center

Related
6 trials

Shared therapeutic areas:

HER2-positive Breast Cancer
Similarity Score5%

Seock-Ah Im, MD, PhD

Seoul National University Hospital

Related
5 trials

Shared therapeutic areas:

Advanced Breast Cancer
Similarity Score5%

Kun Wang, MD

Guangdong Provincial People's Hospital

Related
6 trials

Shared therapeutic areas:

HER2-positive Breast Cancer
Similarity Score5%

Lupe Salazar

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

HER2-positive Breast Cancer
Similarity Score5%

Fei Ma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
6 trials

Shared therapeutic areas:

Advanced Breast Cancer
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06172127Phase 2PrincipalInvestigator

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

HER2-positive Breast Cancer
Active Not Recruiting
NCT07619066Phase 2PrincipalInvestigator

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Advanced Breast CancerHER2 MutationHormone Receptor Positive / HER2-negative Breast Cancer
Not Yet Recruiting

All 2 trials loaded